Can KRAS Positive Colorectal and Lung Cancer Finally be Targeted? - CancerConnect
Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer
Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer | Pharmacogenomics
Chemically modified MIR143-3p exhibited anti-cancer effects by impairing the KRAS network in colorectal cancer cells: Molecular Therapy - Nucleic Acids
Frontiers | Targeting KRAS: The Elephant in the Room of Epithelial Cancers
KRAS Codon 12 Mutation is Associated with More Aggressive Invasiveness | OTT
KRAS Mutation in Colon Cancer: A Marker of Resistance to EGFR-I Therapy | Annals of Surgical Oncology
Differential Reprogramming of Isogenic Colorectal Cancer Cells by Distinct Activating KRAS Mutations | Journal of Proteome Research
Integrated multi-omics characterization of KRAS mutant colorectal cancer
Kras in metastatic colorectal cancer
Life | Free Full-Text | Integrated Decision-Making in the Treatment of Colon-Rectal Cancer: The Case of KRAS-Mutated Tumors
IJMS | Free Full-Text | Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward?
Tumor microenvironment-adjusted prognostic implications of the KRAS mutation subtype in patients with stage III colorectal cancer treated with adjuvant FOLFOX | Scientific Reports
KRAS mutation: from undruggable to druggable in cancer | Signal Transduction and Targeted Therapy
:quality(90)/ "Roche | Cancer du côlon : les principales mutations")
Roche | Cancer du côlon : les principales mutations
Colorectal Cancer | Oncohema Key
The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study - Chida - 2021 - The Oncologist - Wiley Online Library
Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review - Benoist Chibaudel, Christophe Tournigand, Franck Bonnetain, Hubert Richa, Magdalena Benetkiewicz, Thierry André, Aimery de Gramont, 2015
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis - The Lancet Oncology
TAK1 Inhibition Promotes Apoptosis in KRAS-Dependent Colon Cancers - ScienceDirect
Mutations in APC, Kirsten-ras, and p53—alternative genetic pathways to colorectal cancer | PNAS
